18:06 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Mouse studies suggest nanoparticles loaded with an ADORA2A antagonist and conjugated to CAR T cells could help treat ovarian cancer. The conjugate consists of cross-linked multilamellar liposomal nanoparticles loaded with a tool...
02:46 , Mar 24, 2018 |  BioCentury  |  Product Development

Optimism for A2A

Once considered solely a neurology target, the adenosine pathway has attracted interest in immuno-oncology based on its ability to control whether immune cells adopt a stimulatory or suppressive phenotype. The early results from A2A receptor...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
18:18 , Sep 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Ophthalmic Cell culture and mouse studies suggest inhibiting ADORA2A could help treat proliferative retinopathy. In a mouse model of the disease, retinal levels of ADORA2A were higher than in normal mice. In human microvascular...
22:26 , Dec 15, 2016 |  BC Week In Review  |  Clinical News

Nouriast: Ph III data

Top-line data from a double-blind, international Phase III trial in 609 patients with moderate to severe PD and wearing-off phenomena on levodopa therapy showed that once-daily 20 and 40 mg oral istradefylline each missed the...
23:08 , Dec 13, 2016 |  BC Extra  |  Clinical News

Kyowa PD drug misses in global Phase III

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said istradefylline ( KW-6002 ) missed the primary endpoint in a global Phase III trial to treat moderate to severe Parkinson’s disease in patients with "wearing-off" phenomena on levodopa...
07:00 , Aug 17, 2015 |  BioCentury  |  Product Development

Structure knows best

Although most of Heptares' compounds are against clinically validated targets, and only one currently boasts first-in-class potential, the structure-based drug design company is building a case for its ability to expand targets into new indications,...
07:00 , Aug 21, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma; breast cancer; cancer Adenosine A2A receptor (ADORA2A); CTLA-4 (CD152); ecto-5ʹ-nucleotidase (NT5E; NT; CD73); programmed cell death 1 (PDCD1; PD-1; CD279) Mouse studies suggest ADORA2A...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Actin a2 smooth aorta muscle (ACTA2; a-SMA); smoothened (SMO); sonic hedgehog homolog (SHH) Studies in mice and patients suggest depleting tumor stroma and...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Addiction Adenosine A2A receptor (ADORA2A) Nonhuman primate studies suggest antagonists of presynaptic ADORA2A could help treat cannabis addiction. In cannabinoid-addicted nonhuman primates, an antagonist that...